John Fesko Sells 931 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 931 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $236,539.17. Following the completion of the transaction, the insider owned 184,069 shares in the company, valued at approximately $46,766,410.83. The trade was a 0.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The stock was sold at an average price of $202.84, for a total value of $291,683.92.
• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $59,992.56.

Natera Stock Performance

Shares of NASDAQ:NTRA traded up $1.60 during midday trading on Wednesday, reaching $253.82. The company’s stock had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The firm has a 50 day moving average price of $244.16 and a two-hundred day moving average price of $221.65. The firm has a market capitalization of $36.35 billion, a price-to-earnings ratio of -155.72 and a beta of 1.51.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently modified their holdings of NTRA. Robinhood Asset Management LLC acquired a new position in Natera during the fourth quarter worth $12,981,000. UBS Group AG lifted its stake in shares of Natera by 19.4% in the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after buying an additional 71,355 shares in the last quarter. J. Safra Sarasin Holding AG acquired a new position in shares of Natera during the fourth quarter valued at about $2,825,000. ABN Amro Investment Solutions increased its position in shares of Natera by 44.6% during the first quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock worth $1,869,000 after acquiring an additional 2,883 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Natera by 286.8% during the fourth quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock worth $15,055,000 after acquiring an additional 48,728 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on NTRA shares. Sanford C. Bernstein initiated coverage on Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target on the stock. TD Cowen reiterated a “buy” rating on shares of Natera in a research note on Wednesday, July 15th. The Goldman Sachs Group assumed coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 target price on the stock. Royal Bank Of Canada began coverage on shares of Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 target price on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.